基于血清IL-10的多标志物模型预测了胃癌患者对转化免疫化学疗法的反应:一项回顾性队列研究
Xingzhou Wang1, Hang Jiang2, Mengjie Liang1
1Department of Gastric Surgery, Affiliated Drum Tower Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
BMC gastroenterology
|August 27, 2025
概括
在接受转化免疫化疗的晚期胃癌患者中,血清白蛋白和IL-10等血液生物标志物可以预测治疗反应. 监测这些标志物有助于识别敏感患者,并指导那些没有反应的患者采取策略.
科学领域:
- 癌症学
- 胃肠病学
- 免疫疗法
背景情况:
- 转化免疫化疗显示局部晚期胃癌的可能性,但反应率较低.
- 使用血液学生物标志物预测治疗疗效具有挑战性,现有证据有限.
- 这项研究旨在确定治疗反应的预测性血液学生物标志物,并建议对不反应的患者采取策略.
研究的目的:
- 通过血液学生物标志物识别晚期胃癌治疗反应的预测因素.
- 建议针对转化免疫化学疗法不起作用的晚期胃癌患者采取策略.
- 为预测晚期胃癌的瘤回归度 (TRG) 开发一个名图.
主要方法:
- 对153名晚期胃癌患者 (PD- L1阴性,微观卫星稳定) 的临床和实验室数据的回顾性分析.
- 患者接受了转换性免疫化疗,随后进行了急性胃切除术.
- 评估了关键指标与治疗结果之间的相关性;开发了一个名图来预测TRG.
主要成果:
- 用转化免疫化学疗法治疗的晚期胃癌的预后与瘤回归度 (TRG) 有显著的相关性.
- 与TRG相关的关键因素包括高血压,治疗前血清白蛋白,瘤大小和治疗后IL-10,IFN-γ,TNF-α和瘤相关的碳水化合物抗原.
- 高血压,治疗前的血清白蛋白,治疗后的IL-10和与瘤相关的碳水化合物抗原的恢复是TRG的独立预测因素.
结论:
- 血清白蛋白,IL-10和瘤相关碳水化合物抗原的动态监测有助于评估对转化免疫化学疗法的治疗反应.
- 这种监测可以识别对治疗敏感的患者.
- 需要在前性试验中进一步验证,以推针对不反应的患者的具体干预措施.
更多相关视频
相关概念视频
02:43Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.